CN Patent

CN112771032B — 作为第四代egfr抑制剂的嘧啶吡唑类化合物

Assigned to Jiangsu Simcere Pharmaceutical Co Ltd · Expires 2023-01-03 · 3y expired

What this patent protects

公开了第四代(T790M/C797S突变)EGFR激酶抑制剂的新型嘧啶吡唑类化合物及其医药用途，具体公开了式(I)所示化合物、其立体异构体、消旋体、互变异构体、同位素标记物、氮氧化物或其药学上可接受的盐。所述化合物在EGFR Del19/T790M/C797S和L858R/T790M/C797S异常突变引起的疾病上有着较好的疗效。

USPTO Abstract

公开了第四代(T790M/C797S突变)EGFR激酶抑制剂的新型嘧啶吡唑类化合物及其医药用途，具体公开了式(I)所示化合物、其立体异构体、消旋体、互变异构体、同位素标记物、氮氧化物或其药学上可接受的盐。所述化合物在EGFR Del19/T790M/C797S和L858R/T790M/C797S异常突变引起的疾病上有着较好的疗效。

Drugs covered by this patent

Patent Metadata

Patent number
CN112771032B
Jurisdiction
CN
Classification
—
Expires
2023-01-03
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Simcere Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.